Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imaging outcome measures for progressive multiple sclerosis trials.

Marcello Moccia1, Nicola de Stefano2, Frederik Barkhof3

  • 1NMR Research Unit, Queen Square MS Centre, UCL Institute of Neurology, University College London, London, UK; Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|October 19, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2017
Same author

Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment" (TRACE-VCI) Study.

JMIR research protocols·2017
Same author

Altered eigenvector centrality is related to local resting-state network functional connectivity in patients with longstanding type 1 diabetes mellitus.

Human brain mapping·2017
Same author

Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2017
Same author

Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET.

European radiology·2017
Same author

Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

Neurobiology of aging·2017
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Interaction between smoking and <i>HLA-A*02:01</i> in multiple sclerosis progression.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles
This summary is machine-generated.

Reliable imaging markers are crucial for developing new neuroprotective medications for progressive multiple sclerosis (MS). Advanced MRI techniques show promise for reflecting specific pathological changes in clinical trials.

Area of Science:

  • Neuroimaging
  • Neurology
  • Clinical Trials

Background:

  • Reliable, reproducible, and sensitive imaging markers are essential for advancing neuroprotective treatments in progressive multiple sclerosis (MS).
  • Numerous imaging biomarkers are now incorporated into phase 2 and 3 clinical trials for primary and secondary progressive MS.

Purpose of the Study:

  • To discuss the applications, limitations, and future perspectives of various imaging techniques in clinical trials for progressive MS.
  • To emphasize the importance of measurement sensitivity, reliability, and sample size calculation for these imaging markers.

Main Methods:

  • Review of established imaging markers: brain lesion count and volume, reflecting inflammation and demyelination.
  • Discussion of emerging markers: brain and spinal cord atrophy, strongly associated with disability.
Keywords:
Multiple sclerosisimagingoutcomeprogressivetrial

Related Experiment Videos

  • Exploration of advanced magnetic resonance imaging (MRI) techniques like magnetization transfer ratio (MTR), diffusion tensor imaging (DTI), and spectroscopy for detecting specific pathological changes.

    • Main Results:

    • Brain lesion count and volume remain important outcomes in progressive MS trials.
    • Spinal cord atrophy analysis methods are improving, enhancing their clinical trial applicability.
    • Advanced MRI techniques show potential for reflecting targeted pathological changes, though their trial inclusion is currently limited.

    Conclusions:

    • Imaging markers are vital for developing and testing neuroprotective therapies in progressive MS.
    • Continued refinement of analysis methods and exploration of advanced techniques will improve trial sensitivity and efficiency.
    • Techniques like positron emission tomography (PET) and optical coherence tomography require further evaluation for trial integration.